article thumbnail

Illingworth: mobile nursing can reduce trial patient burden

Outsourcing Pharma

A leader from home-based clinical services firm Illingworth Research Group talks about the evolution of mobile nursing and how it can keep trials going.

Nurses 97
article thumbnail

How Can You Manage the Complexity of Early Phase Clinical Development?

XTalks

Oren Cohen, MD, FIDSA CMO & President of Clinical Pharmacology Fortrea Fortrea is a provider of comprehensive Phase I through IV clinical trial management, clinical pharmacology, market access solutions and other enabling services. They are unique and require specific expertise.” FIH studies involve a lot of risk.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Finding the right partners key to decentralized trials: Illingworth

Outsourcing Pharma

A leader from the mobile research nursing specialist offers advice on what to look for in a service provider, and why finding the right one is vital.

Nurses 59
article thumbnail

?5 Things You Need to Know from Our Recent Gene Therapy Webinar

Worldwide Clinical Trials

We’ve also seen a decrease in available research nurses, as they have had to be reassigned to COVID patients. It really is—there has been a 10x increase in cell and gene therapies in the clinical development pipeline since 2012. Fewer staff creates many problems, including less bandwidth to meet for reviews and approvals.

article thumbnail

Unlocking the potential in rare disease research with decentralised trials

pharmaphorum

Clearly, face-to-face visits will still be necessary, but through a decentralised approach these can be limited and balanced with home visits from nurses or by engaging local clinics and hospitals so some appointments can be conducted at the patient’s regular doctor’s office.

Trials 133
article thumbnail

Co-inspiration: Listen and learn to overcome patient-centricity barriers

pharmaphorum

One example of patient centricity in action at Boehringer Ingelheim is how the company has changed its clinical trial communications policies, she said. Patients are experts in their disease, not in clinical development. As well as digital tools and nurse visits, they sometimes wanted to see the doctor,” she said.

article thumbnail

Benefits of Artificial Intelligence for Clinical Research Will Require Human Touch Along the Way

ACRP blog

“From AI and machine learning producing an era of rapid new pathways, to an industry-wide push for equitable representation in clinical trials, 2023 will be a catalytic year for biopharma clinical development and commercialization,” the company notes in its press release on this, its 13th annual trends report.